Free Daily Podcast Summary
Oncology News Central Peer-Spectives: Daily Summaries Delivered
by Oncololgy News Central
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Apr 29, 202610 min
“Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care
In the wake of recent key data about ESR1-mutated metastatic breast cancer, treatment decisions have become more complicated. “In current clinical practice, this is not a straightforward decision,” Marla Lipsyc-Sharf, MD, explains to Robert A. Figlin, MD.
- Apr 21, 20269 min
New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
“In breast cancer now, all of our treatment for hormone receptor–positive metastatic disease is a bit of a moving target because of new therapies that are available,” explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women’s Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte, California. She discusses the “ever-changing” landscape involving the PI3 kinase/AKT/mTOR pathway with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. Dr. Rugo details key considerations that she uses for decision making in practice. “And I think we just want to be cautious about toxicity for these patients and really know that we’re benefiting them, rather than using up treatments,” she explains.
- Apr 17, 202612 min
Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
As the management of patients with ESR1-mutated metastatic breast cancer evolves, various questions have emerged in clinical practice. “It's a complex situation,” explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte, California. She discusses how recent advances have changed treatment decisions with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today we just have single-agent oral SERDs, and people like to give combinations,” Dr. Rugo notes. But what combinations to give and when remains unclear. “I think how we're going to decide is that we're going to wait and see what's approved and then look at patients to try and figure out what to do,” she offers.
- Apr 2, 202614 min
Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
How are oncologists currently approaching the care of patients with ESR1-mutated advanced breast cancer in practice? Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, speaks with Wassim Mchayleh, MD, MBA, the clinical program director of the breast cancer program at AdventHealth Cancer Institute and associate professor of medicine at the University of Central Florida in Orlando, about how to best use oral selective estrogen receptor degraders. “And the big question is ‘Can we use SERDs in combination, or are SERDs effective in patients without an ESR1 mutation?’ Can we go outside the current approved guidelines? And I think that’s the biggest question that everyone is asking today,” notes Dr. Mchayleh.
- Dec 18, 202511 min
Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He describes the options available for prophylaxis and how he treats the toxicities that do arise.
- Dec 18, 202514 min
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective for patients and also from a longevity perspective,” explains Sid Devarakonda, MD, director of thoracic medical oncology at Swedish Cancer Institute in Seattle and clinical associate professor at Washington State University. He speaks with Aakash Desai, MD, MPH, associate director of the Phase 1 and Precision Oncology program at the University of Alabama at Birmingham, about how CNS metastases inform choices between regimens. Dr. Devarakonda also discusses how the recent U.S. Food and Drug Administration approval of subcutaneous amivantamab (Rybrevant Faspro) may change his approach. “[Y]ou still need to be comfortable managing some of the toxicities that still persist, even with the subcutaneous formulation, but it's terribly convenient from a practical perspective,” he notes. Dr. Desai and Dr. Devarakonda reported various financial relationships.
- Dec 16, 202512 min
“Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
With multiple regimens available for advanced EGFRm NSCLC, selecting the best regimen for an individual patient is key. Jorge Nieva, MD, tells host Aakash Desai, MD, MPH, that the question shouldn’t be about who needs more efficacy, but rather understanding a patient’s personality and goals.
- Dec 15, 202515 min
As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty?
Progress in cancer care means that millions of patients are living longer lives, albeit without hope of a cure. What role can oncologists and other physicians play in helping to navigate these uncertain futures? “What is our obligation to them? How do we understand them and their needs and respond to them?” asks Sunita Puri, MD, author of That Good Night: Life and Medicine in the Eleventh Hour and associate professor of medicine and director of the inpatient palliative care service at the University of California Irvine School of Medicine. She discusses how she uses “radical honesty” with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer Center in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology. Dr. Puri explains how she admits her own limitations when helping patients who are grappling with questions about what treatments mean for quality vs quantity of life. “I want to be a resource to you, but I also want you to know I share in your uncertainty because I’m not sure what’s going to happen next.” Dr. Puri reported no relevant financial relationships. Dr. Figlin reported various financial relationships.
Get Oncology News Central Peer-Spectives summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
Becker’s Healthcare Podcast
Daily 15-minute episodes covering U.S. healthcare news, analysis, and insights from industry leaders.
Health Discovered
Doctors explore surprising stories to uncover insights about health and well-being.
Plenary Session
Discusses medicine, oncology, and health policy with expert guests and critical analysis.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
The Empowering Neurologist Podcast
Explores health and wellness through interviews with leading experts in the field.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
CSPI Podcast
Conversations with CSPI scholars and experts on topics in science, technology, and politics.
This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.
Treated with Dr. Sara Szal
Dr. Sara Szal explores holistic health solutions through conversations with experts and patients seeking mind, body, and soul healing.
The Internet Book of Critical Care Podcast
A podcast exploring critical care medicine through chapter discussions and evidence-based updates from The Internet Book of Critical Care.
About Oncology News Central Peer-Spectives
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Oncology News Central Peer-Spectives in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Oncology News Central Peer-Spectives daily summary?
It's a free AI-powered email that summarizes new episodes of Oncology News Central Peer-Spectives as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Oncology News Central Peer-Spectives podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Oncology News Central Peer-Spectives product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Oncololgy News Central.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Oncology News Central Peer-Spectives release new episodes?
Oncology News Central Peer-Spectives publishes 2x weekly. Our AI generates a summary within hours of each new episode.
What topics does Oncology News Central Peer-Spectives cover?
Oncology News Central Peer-Spectives covers topics including Science. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Oncology News Central Peer-Spectives summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.